Who Paid My Doc
Nakhle Saba
Hematology & Oncology Baton Rouge, LA Medical Doctor
NPI 1275714669 CMS profile 1297710
7777 Hennessy Blvd Ste 212, Baton Rouge, LA 70808
General payments
$842,031
Research payments
$1,273
Ownership & investment interest
$0
Research they led as principal investigator
$1,602,327
Through program year 2025, Nakhle Saba of Baton Rouge, LA is reported in the CMS Open Payments database as having received $842,031 across 1,053 general payments and $1,273 in research payments paid to them. Separately, studies naming them as principal investigator received $1,602,327 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $104,798 | 144 | |
| 2024 | General | $182,637 | 212 | |
| 2024 | Research | $1,233 | 2 | |
| 2023 | General | $133,172 | 159 | |
| 2022 | General | $187,662 | 203 | |
| 2022 | Research | $40 | 1 | |
| 2021 | General | $59,493 | 55 | |
| 2020 | General | $57,925 | 78 | |
| 2019 | General | $116,344 | 202 |
Beside peers
- Nakhle Saba
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Nakhle Saba were reported at $104,798. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Nakhle Saba | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $116,344 | $529 | $121–$2,516 | $163 |
| 2020 | $57,925 | $339 | $82–$2,213 | $114 |
| 2021 | $59,493 | $263 | $49–$1,965 | $132 |
| 2022 | $187,662 | $416 | $103–$2,395 | $149 |
| 2023 | $133,172 | $542 | $125–$2,646 | $160 |
| 2024 | $182,637 | $692 | $141–$3,008 | $164 |
| 2025 | $104,798 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$19,400
Medicare patients
52
Services billed
240
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 31% | |
| Arthritis | 29% | |
| Atrial fibrillation | 25% | |
| Diabetes | 23% | |
| COPD | 23% | |
| Cancer | 23% | |
| Chronic kidney disease | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 36 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VENCLEXTA |
|
$55,687 | — | — |
| BRUKINSA |
|
$55,342 | — | — |
| JAYPIRCA |
|
$48,307 | — | — |
| TAZVERIK |
|
$2,175 | — | — |
| IMBRUVICA |
|
$1,358 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 36 with PatronRecords
1,056 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Louisiana
Hana Safah
Hematology & Oncology · Baton Rouge, LA
Pedro Barata
Hematology & Oncology · New Orleans, LA
Maissaa Janbain
Hematology & Oncology · New Orleans, LA
Marc Matrana
Hematology & Oncology · New Orleans, LA
Prakash Peddi
Hematology & Oncology · Shreveport, LA
Sanjay Juneja
Hematology & Oncology · Baton Rouge, LA
Related records
Hematology & Oncology in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.